These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 8191398

  • 1. Familial idiopathic osteonecrosis mediated by familial hypofibrinolysis with high levels of plasminogen activator inhibitor.
    Glueck CJ, Glueck HI, Welch M, Freiberg R, Tracy T, Hamer T, Stroop D.
    Thromb Haemost; 1994 Feb; 71(2):195-8. PubMed ID: 8191398
    [Abstract] [Full Text] [Related]

  • 2. Familial high plasminogen activator inhibitor with hypofibrinolysis, a new pathophysiologic cause of osteonecrosis?
    Glueck CJ, Glueck HI, Mieczkowski L, Tracy T, Speirs J, Stroop D.
    Thromb Haemost; 1993 May 03; 69(5):460-5. PubMed ID: 8322268
    [Abstract] [Full Text] [Related]

  • 3. Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism.
    Grimaudo V, Bachmann F, Hauert J, Christe MA, Kruithof EK.
    Thromb Haemost; 1992 Apr 02; 67(4):397-401. PubMed ID: 1631786
    [Abstract] [Full Text] [Related]

  • 4. Thrombophilia and hypofibrinolysis: pathophysiologies of osteonecrosis.
    Glueck CJ, Freiberg R, Tracy T, Stroop D, Wang P.
    Clin Orthop Relat Res; 1997 Jan 02; (334):43-56. PubMed ID: 9005895
    [Abstract] [Full Text] [Related]

  • 5. Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with Stanozolol.
    Glueck CJ, Freiberg R, Glueck HI, Tracy T, Stroop D, Wang Y.
    Am J Hematol; 1995 Apr 02; 48(4):213-20. PubMed ID: 7717367
    [Abstract] [Full Text] [Related]

  • 6. Hypofibrinolysis: a common, major cause of osteonecrosis.
    Glueck CJ, Freiberg R, Glueck HI, Henderson C, Welch M, Tracy T, Stroop D, Hamer T, Sosa F, Levy M.
    Am J Hematol; 1994 Feb 02; 45(2):156-66. PubMed ID: 8141121
    [Abstract] [Full Text] [Related]

  • 7. Procoagulants and osteonecrosis.
    Jones LC, Mont MA, Le TB, Petri M, Hungerford DS, Wang P, Glueck CJ.
    J Rheumatol; 2003 Apr 02; 30(4):783-91. PubMed ID: 12672200
    [Abstract] [Full Text] [Related]

  • 8. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.
    Sebestjen M, Zegura B, Guzic-Salobir B, Keber I.
    Wien Klin Wochenschr; 2001 Feb 15; 113(3-4):113-8. PubMed ID: 11253736
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Familial association of high levels of histidine-rich glycoprotein and plasminogen activator inhibitor-1 with venous thromboembolism.
    Angles-Cano E, Gris JC, Loyau S, Schved JF.
    J Lab Clin Med; 1993 May 15; 121(5):646-53. PubMed ID: 8478593
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men.
    Glueck CJ, Glueck HI, Stroop D, Speirs J, Hamer T, Tracy T.
    J Lab Clin Med; 1993 Oct 15; 122(4):412-20. PubMed ID: 8228555
    [Abstract] [Full Text] [Related]

  • 16. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.
    Sartori MT, Wiman B, Vettore S, Dazzi F, Girolami A, Patrassi GM.
    Thromb Haemost; 1998 Dec 15; 80(6):956-60. PubMed ID: 9869167
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
    van der Bom JG, Bots ML, Haverkate F, Meyer P, Hofman A, Grobbee DE, Kluft C.
    Thromb Haemost; 1999 Feb 15; 81(2):275-80. PubMed ID: 10064006
    [Abstract] [Full Text] [Related]

  • 20. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
    Johansson JO, Landin K, Johannsson G, Tengborn L, Bengtsson BA.
    Thromb Haemost; 1996 Sep 15; 76(3):422-8. PubMed ID: 8883281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.